Industry News

Join WhatsApp Channel 

GPAT caoching

  • Ajanta Pharma, a Rs. 1,450 crore plus Mumbai based pharma major, has received the third largest wealth creator award from Fortune India. Fortune India has published list of 500 mid-size companies and ranked them on various parameters based on the results of 2013-14. Similarly, Ajanta Pharma ranked tenth on return on capital employed, 21st in net profit and 182nd in sales.

    [adsense:336x280:8701650588]

  • In India OXXY launch hospital chain
    25 August 2015
    In India OXXY launch hospital chain

    OXXY, with over 1 lakh medical centres already tied up under its belt, is all set to launch its hospital chain in India. OXXY, valued over USD 2 billion, is all set to launch hospitals in the metros and a few other cities under its belt in next few months. These hospitals will be from 50 bedded to 500 bedded capacity. No other model currently exists in India and its success will purely depend on the affordability of quality treatment and services directly in comparison with the global standards.

  • The US Food and Drug Administration (FDA) has accepted leading global pharmaceutical company, Teva Pharmaceutical Industries Ltd's New Drug Application (NDA) for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). It is  a rare and fatal neurodegenerative disorder caused by the progressive breakdown of nerve cells in the brain that affects about five to seven people per 100,000 in western countries, according to the World Health Organisation.

  • focus in the areas of pain management and addiction medicine, announced the approval by the US Food and Drug Administration (FDA) of a Supplemental New Drug Application (sNDA) for a new formulation of Onsolis (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant. Onsolis is separately licensed by BDSI in Taiwan and South Korea.

  • Dabur India Ltd, in an effort to ensure maximum use of its leading mosquito repellant Odomos, has unveiled the Dengue-Fighters initiative aimed at preventing school-going children across the country. The company along with Apollo Hospitals Group began its campaign in Bengaluru, which will then cover schools across Delhi, Uttar Pradesh, Maharashtra and Tamil Nadu.

  • A new medication to be launched by the end of this year by US Pharma major Eli Lilly, for diabetic patients in India. A regulatory approval for the upcoming product has already been received by the company. It is also gearing up to introduce another medication in oncology that could be launched by the end of 2016 or early 2017 which has been filed for approvals.

Subscribe to Industry News